Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: The antibody factor

Carmen Gomez-Fernandez, Aldo Mejias, Gail Walker, Mehrdad Nadji

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

BACKGROUND: Immunohistochemistry for estrogen receptor may be used to distinguish metastatic breast cancers from adenocarcinomas of other sites, including those of the lung. The estrogen receptor exists as 2 subtypes, α and β. Estrogen receptor α is the predominant subtype expressed by more than two-thirds of human breast cancers. Adenocarcinomas of lung origin may also express estrogen receptor, primarily the β subtype. Human estrogen receptor α is highly homologous to estrogen receptor β and consequently, antibodies used to detect estrogen receptor α in breast carcinomas may detect estrogen receptor β in pulmonary adenocarcinomas. We investigated the immunohistochemical expression of estrogen receptor in proven primary lung adenocarcinomas using 3 anti-estrogen receptor α antibodies: mouse monoclonal 1D5, 6F11, and rabbit monoclonal SP1. DESIGN: Ninety-two pulmonary adenocarcinomas (53 women and 39 men) confirmed by clinical presentation and positive immunohistochemistry for thyroid transcription factor-1 (TTF-1) were included in this study. There were 19 incisional biopsies and 73 excisional specimens. Immunohistochemistry for estrogen receptor using antibodies 1D5, 6F11, and SP1 was performed on formalin-fixed, paraffin-embedded tissue following antigen retrieval. Any nuclear reactivity for estrogen receptor was considered a positive result. RESULT: Focal positive nuclear reaction for estrogen receptor was detected in 7 (7.6%) cases of primary pulmonary adenocarcinoma using antibody 1D5, 13 (14.1%) using 6F11, and 25 (27.2%) using SP1. The differences in reactivity for estrogen receptor in pulmonary adenocarcinomas between SP1 and 1D5, and between SP1 and 6F11 were statistically significant (P<0.001). Positive cases showed only a focal pattern of staining with each of the 3 antibodies. There was no significant difference in reactivity for estrogen receptor in pulmonary adenocarcinomas of men and women. Positive staining was highest in nonmucinous bronchioloalveolar adenocarcinomas for all of the antibodies, and for SP1, variation by histologic subtype was significant (P<0.001). CONCLUSIONS: SP1 has a significantly higher detection rate for the expression of estrogen receptor in pulmonary adenocarcinomas when compared with either 1D5 or 6F11. Caution should therefore be exercised in the use of this antibody alone in distinguishing a metastatic breast from a primary pulmonary adenocarcinoma.

Original languageEnglish
Pages (from-to)137-141
Number of pages5
JournalApplied Immunohistochemistry and Molecular Morphology
Volume18
Issue number2
DOIs
StatePublished - Mar 1 2010

Fingerprint

Estrogen Receptors
Antibodies
Adenocarcinoma of lung
Immunohistochemistry
Breast Neoplasms
Adenocarcinoma
Staining and Labeling
Paraffin
Formaldehyde
Breast

Keywords

  • Estrogen receptor
  • Immunohistochemistry
  • Pulmonary adenocarcinomas

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology

Cite this

@article{d84d6ef4eff5431c8f98c8d10b7fe080,
title = "Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung: The antibody factor",
abstract = "BACKGROUND: Immunohistochemistry for estrogen receptor may be used to distinguish metastatic breast cancers from adenocarcinomas of other sites, including those of the lung. The estrogen receptor exists as 2 subtypes, α and β. Estrogen receptor α is the predominant subtype expressed by more than two-thirds of human breast cancers. Adenocarcinomas of lung origin may also express estrogen receptor, primarily the β subtype. Human estrogen receptor α is highly homologous to estrogen receptor β and consequently, antibodies used to detect estrogen receptor α in breast carcinomas may detect estrogen receptor β in pulmonary adenocarcinomas. We investigated the immunohistochemical expression of estrogen receptor in proven primary lung adenocarcinomas using 3 anti-estrogen receptor α antibodies: mouse monoclonal 1D5, 6F11, and rabbit monoclonal SP1. DESIGN: Ninety-two pulmonary adenocarcinomas (53 women and 39 men) confirmed by clinical presentation and positive immunohistochemistry for thyroid transcription factor-1 (TTF-1) were included in this study. There were 19 incisional biopsies and 73 excisional specimens. Immunohistochemistry for estrogen receptor using antibodies 1D5, 6F11, and SP1 was performed on formalin-fixed, paraffin-embedded tissue following antigen retrieval. Any nuclear reactivity for estrogen receptor was considered a positive result. RESULT: Focal positive nuclear reaction for estrogen receptor was detected in 7 (7.6{\%}) cases of primary pulmonary adenocarcinoma using antibody 1D5, 13 (14.1{\%}) using 6F11, and 25 (27.2{\%}) using SP1. The differences in reactivity for estrogen receptor in pulmonary adenocarcinomas between SP1 and 1D5, and between SP1 and 6F11 were statistically significant (P<0.001). Positive cases showed only a focal pattern of staining with each of the 3 antibodies. There was no significant difference in reactivity for estrogen receptor in pulmonary adenocarcinomas of men and women. Positive staining was highest in nonmucinous bronchioloalveolar adenocarcinomas for all of the antibodies, and for SP1, variation by histologic subtype was significant (P<0.001). CONCLUSIONS: SP1 has a significantly higher detection rate for the expression of estrogen receptor in pulmonary adenocarcinomas when compared with either 1D5 or 6F11. Caution should therefore be exercised in the use of this antibody alone in distinguishing a metastatic breast from a primary pulmonary adenocarcinoma.",
keywords = "Estrogen receptor, Immunohistochemistry, Pulmonary adenocarcinomas",
author = "Carmen Gomez-Fernandez and Aldo Mejias and Gail Walker and Mehrdad Nadji",
year = "2010",
month = "3",
day = "1",
doi = "10.1097/PAI.0b013e3181bec23b",
language = "English",
volume = "18",
pages = "137--141",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Immunohistochemical expression of estrogen receptor in adenocarcinomas of the lung

T2 - The antibody factor

AU - Gomez-Fernandez, Carmen

AU - Mejias, Aldo

AU - Walker, Gail

AU - Nadji, Mehrdad

PY - 2010/3/1

Y1 - 2010/3/1

N2 - BACKGROUND: Immunohistochemistry for estrogen receptor may be used to distinguish metastatic breast cancers from adenocarcinomas of other sites, including those of the lung. The estrogen receptor exists as 2 subtypes, α and β. Estrogen receptor α is the predominant subtype expressed by more than two-thirds of human breast cancers. Adenocarcinomas of lung origin may also express estrogen receptor, primarily the β subtype. Human estrogen receptor α is highly homologous to estrogen receptor β and consequently, antibodies used to detect estrogen receptor α in breast carcinomas may detect estrogen receptor β in pulmonary adenocarcinomas. We investigated the immunohistochemical expression of estrogen receptor in proven primary lung adenocarcinomas using 3 anti-estrogen receptor α antibodies: mouse monoclonal 1D5, 6F11, and rabbit monoclonal SP1. DESIGN: Ninety-two pulmonary adenocarcinomas (53 women and 39 men) confirmed by clinical presentation and positive immunohistochemistry for thyroid transcription factor-1 (TTF-1) were included in this study. There were 19 incisional biopsies and 73 excisional specimens. Immunohistochemistry for estrogen receptor using antibodies 1D5, 6F11, and SP1 was performed on formalin-fixed, paraffin-embedded tissue following antigen retrieval. Any nuclear reactivity for estrogen receptor was considered a positive result. RESULT: Focal positive nuclear reaction for estrogen receptor was detected in 7 (7.6%) cases of primary pulmonary adenocarcinoma using antibody 1D5, 13 (14.1%) using 6F11, and 25 (27.2%) using SP1. The differences in reactivity for estrogen receptor in pulmonary adenocarcinomas between SP1 and 1D5, and between SP1 and 6F11 were statistically significant (P<0.001). Positive cases showed only a focal pattern of staining with each of the 3 antibodies. There was no significant difference in reactivity for estrogen receptor in pulmonary adenocarcinomas of men and women. Positive staining was highest in nonmucinous bronchioloalveolar adenocarcinomas for all of the antibodies, and for SP1, variation by histologic subtype was significant (P<0.001). CONCLUSIONS: SP1 has a significantly higher detection rate for the expression of estrogen receptor in pulmonary adenocarcinomas when compared with either 1D5 or 6F11. Caution should therefore be exercised in the use of this antibody alone in distinguishing a metastatic breast from a primary pulmonary adenocarcinoma.

AB - BACKGROUND: Immunohistochemistry for estrogen receptor may be used to distinguish metastatic breast cancers from adenocarcinomas of other sites, including those of the lung. The estrogen receptor exists as 2 subtypes, α and β. Estrogen receptor α is the predominant subtype expressed by more than two-thirds of human breast cancers. Adenocarcinomas of lung origin may also express estrogen receptor, primarily the β subtype. Human estrogen receptor α is highly homologous to estrogen receptor β and consequently, antibodies used to detect estrogen receptor α in breast carcinomas may detect estrogen receptor β in pulmonary adenocarcinomas. We investigated the immunohistochemical expression of estrogen receptor in proven primary lung adenocarcinomas using 3 anti-estrogen receptor α antibodies: mouse monoclonal 1D5, 6F11, and rabbit monoclonal SP1. DESIGN: Ninety-two pulmonary adenocarcinomas (53 women and 39 men) confirmed by clinical presentation and positive immunohistochemistry for thyroid transcription factor-1 (TTF-1) were included in this study. There were 19 incisional biopsies and 73 excisional specimens. Immunohistochemistry for estrogen receptor using antibodies 1D5, 6F11, and SP1 was performed on formalin-fixed, paraffin-embedded tissue following antigen retrieval. Any nuclear reactivity for estrogen receptor was considered a positive result. RESULT: Focal positive nuclear reaction for estrogen receptor was detected in 7 (7.6%) cases of primary pulmonary adenocarcinoma using antibody 1D5, 13 (14.1%) using 6F11, and 25 (27.2%) using SP1. The differences in reactivity for estrogen receptor in pulmonary adenocarcinomas between SP1 and 1D5, and between SP1 and 6F11 were statistically significant (P<0.001). Positive cases showed only a focal pattern of staining with each of the 3 antibodies. There was no significant difference in reactivity for estrogen receptor in pulmonary adenocarcinomas of men and women. Positive staining was highest in nonmucinous bronchioloalveolar adenocarcinomas for all of the antibodies, and for SP1, variation by histologic subtype was significant (P<0.001). CONCLUSIONS: SP1 has a significantly higher detection rate for the expression of estrogen receptor in pulmonary adenocarcinomas when compared with either 1D5 or 6F11. Caution should therefore be exercised in the use of this antibody alone in distinguishing a metastatic breast from a primary pulmonary adenocarcinoma.

KW - Estrogen receptor

KW - Immunohistochemistry

KW - Pulmonary adenocarcinomas

UR - http://www.scopus.com/inward/record.url?scp=77649157230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649157230&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e3181bec23b

DO - 10.1097/PAI.0b013e3181bec23b

M3 - Article

C2 - 19875957

AN - SCOPUS:77649157230

VL - 18

SP - 137

EP - 141

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 2

ER -